{"id":"calcium-gluconate","rwe":[{"pmid":"41869998","year":"2026","title":"Hypocalcaemic Tetany and Seizures Secondary to Vitamin D Deficiency.","finding":"","journal":"Irish medical journal","studyType":"Clinical Study"},{"pmid":"41800300","year":"2026","title":"Case Report: long-term calcaemia management in a dog after thyroidectomy and parathyroidectomy.","finding":"","journal":"Frontiers in veterinary science","studyType":"Clinical Study"},{"pmid":"41798656","year":"2026","title":"Hydrofluoric Acid Cutaneous Burns: A Systematic Review of Emergency Management and General Surgical Sequelae.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"41795097","year":"2026","title":"Which calcium preparation should we use in paediatric resuscitation? A comprehensive review of basic physiology, pharmacokinetics, and clinical evidence.","finding":"","journal":"Journal of anesthesia, analgesia and critical care","studyType":"Clinical Study"},{"pmid":"41783629","year":"2025","title":"Multiple Subcutaneous Calcifications in a Neonate after Intravenous Calcium Gluconate: A Case Report.","finding":"","journal":"JNMA; journal of the Nepal Medical Association","studyType":"Clinical Study"}],"_fda":{"id":"323609e8-1364-4118-a016-89ba36e5ce2b","set_id":"0deed071-d89d-420e-b4b4-797dce0ad8f0","openfda":{"upc":["0344567620029"],"unii":["CZN0MI5R31"],"route":["INTRAVENOUS"],"rxcui":["2117608","2117610"],"spl_id":["323609e8-1364-4118-a016-89ba36e5ce2b"],"brand_name":["Calcium Gluconate in Sodium Chloride"],"spl_set_id":["0deed071-d89d-420e-b4b4-797dce0ad8f0"],"package_ndc":["44567-620-02","44567-620-84","44567-621-02","44567-621-84"],"product_ndc":["44567-620","44567-621"],"generic_name":["CALCIUM GLUCONATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["CALCIUM GLUCONATE MONOHYDRATE"],"manufacturer_name":["WG Critical Care, LLC"],"application_number":["NDA210906"],"is_original_packager":[true]},"version":"3","pregnancy":["8.1 Pregnancy Risk summary Limited available data with Calcium Gluconate Injection use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. There are risks to the mother and the fetus associated with hypocalcemia in pregnancy [see Clinical Considerations] . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Disease-associated maternal risk Maternal hypocalcemia can result in an increased rate of spontaneous abortion, premature and dysfunctional labor, and possibly preeclampsia. Fetal/Neonatal adverse reactions Infants born to mothers with hypocalcemia can have associated fetal and neonatal hyperparathyroidism, which in turn can cause fetal and neonatal skeletal demineralization, subperiosteal bone resorption, osteitis fibrosa cystica and neonatal seizures. Infants born to mothers with hypocalcemia should be carefully monitored for signs of hypocalcemia or hypercalcemia, including neuromuscular irritability, apnea, cyanosis and cardiac rhythm disorders."],"overdosage":["10 OVERDOSAGE Overdosage of Calcium Gluconate in Sodium Chloride Injection may result in hypercalcemia. Symptoms of hypercalcemia typically develop when the total serum calcium concentration is ≥12 mg/dL. Neurologic symptoms include depression, weakness, fatigue, and confusion at lower levels, with patients experiencing hallucinations, disorientation, hypotonicity, seizures, and coma. Effects on the kidney include diminished ability to concentrate urine and diuresis. If overdose of Calcium Gluconate in Sodium Chloride Injection occurs immediately discontinue administration and provide supportive treatments to restore intravascular volume as well as promote calcium excretion in the urine if necessary."],"description":["11 DESCRIPTION Calcium Gluconate in Sodium Chloride Injection is a sterile, preservative-free, nonpyrogenic solution of calcium gluconate, a form of calcium, for intravenous use. Calcium Gluconate is calcium D-gluconate (1:2) monohydrate. The structural formula is: Molecular formula: C 12 H 22 CaO 14 • H 2 O Molecular weight: 448.39 Solubility in water: 3.5 g/100 mL at 25°C Calcium Gluconate in Sodium Chloride Injection is available as 1,000 mg per 50 mL (equivalent to 18.8 mg per mL calcium gluconate anhydrous), 2,000 mg per 100 mL (equivalent to 18.8 mg per mL calcium gluconate anhydrous) in single-dose bags. Table 3. Calcium Gluconate Formulations 1,000 mg per 50 mL 2,000 mg per 100 mL Calcium Gluconate 20 mg per mL 20 mg per mL Elemental Calcium 1.86 mg per mL 1.86 mg per mL Sodium Chloride 6.75 mg per mL 6.75 mg per mL Hydrochloric Acid or Sodium Hydroxide pH adjusted 6.0 to 8.2 calcium gluconate structural formula"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Calcium Gluconate in Sodium Chloride Injection is a clear, colorless solution supplied in single-dose bags with an aluminum overwrap available as: Total Strength per Total Volume Strength per mL 24 single-dose bags NDC Bag and Overwrap NDC 1,000 mg per 50 mL 20 mg/mL 44567-620-84* 44567-620-02 2,000 mg per 100 mL 20 mg/mL 44567-621-84 44567-621-02 *partial fill container 50 mL volume in a 100 mL container. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Do not freeze. Product should be used within 60 days of removal from aluminum overwrap. Preservative-free. Discard any unused portion in the single-dose bag immediately."],"geriatric_use":["8.5 Geriatric Use In general dose selection for an elderly patient should start at the lowest dose of the recommended dose range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of Calcium Gluconate in Sodium Chloride Injection have been established in pediatric patients for the treatment of acute, symptomatic hypocalcemia. Pediatric approval for Calcium Gluconate in Sodium Chloride Injection, including doses, is not based on adequate and well-controlled clinical studies. Safety and dosing recommendations in pediatric patients are based on published literature and clinical experience [see Dosage and Administration (2.2)] . Concomitant use of ceftriaxone and Calcium Gluconate in Sodium Chloride Injection is contraindicated in neonates (28 days of age or younger) due to reports of fatal outcomes associated with the presence of lung and kidney ceftriaxone-calcium precipitates. In patients older than 28 days of age, ceftriaxone and Calcium Gluconate Injection may be administered sequentially, provided the infusion lines are thoroughly flushed between infusions with a compatible fluid [ see Contraindications (4) and Warnings and Precautions (5.2)] . This product contains up to 25 mcg/L aluminum which may be toxic, particularly for premature neonates due to immature renal function. Parenteral administration of aluminum greater than 4 mcg/kg/day to 5 mcg/kg/day is associated with central nervous system and bone toxicity [see Warnings and Precautions (5.5)] ."],"effective_time":"20231130","pharmacokinetics":["12.3 Pharmacokinetics Absorption Calcium Gluconate Injection is 100% bioavailable following intravenous injection. Metabolism Calcium itself does not undergo direct metabolism. The release of ionized calcium from intravenous administration of calcium gluconate is direct and does not seem to be affected by the first pass through the liver. Distribution Calcium in the body is distributed mainly in skeleton (99%). Only 1% of the total body calcium is distributed within the extracellular fluids and soft tissues. About 50% of total serum calcium is in the ionized form and represents the biologically active part. 8% to 10% serum calcium is bound to organic and inorganic acid and approximately 40% is protein-bound (primarily to albumin). Elimination Studies have shown a relationship between urinary calcium excretion and the intravenous administration of calcium gluconate, with a significant increase in urinary calcium excretion observed after the intravenous administration of calcium gluconate."],"adverse_reactions":["6 ADVERSE REACTIONS The following serious adverse reactions are also described elsewhere in the labeling: • Arrhythmias with Concomitant Cardiac Glycoside Use [see Warnings and Precautions (5.1)] • End-Organ Damage due to Intravascular Ceftriaxone-Calcium Precipitates [see Warnings and Precautions (5.2)] • Tissue Necrosis and Calcinosis [see Warnings and Precautions (5.3)] • Hypotension, Bradycardia, and Cardiac Arrhythmias [see Warnings and Precautions (5.4)] • Aluminum toxicity [see Warnings and Precautions (5.5)] The following adverse reactions associated with the use of calcium gluconate were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure. Cardiovascular : Vasodilation, decreased blood pressure, bradycardia, cardiac arrhythmia, syncope, cardiac arrest Administration site reactions : Local soft tissue inflammation, local necrosis, calcinosis cutis and calcification due to extravasation The most common adverse events with Calcium Gluconate Injection are local soft tissue inflammation and necrosis, calcinosis cutis and calcification that are related to extravasation. Other adverse events include vasodilation, decreased blood pressure, bradycardia, cardiac arrhythmia, syncope, and cardiac arrest. (6) To report SUSPECTED ADVERSE REACTIONS, contact WG Critical Care, LLC at 1-866-562-4708 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["4 CONTRAINDICATIONS Calcium Gluconate in Sodium Chloride Injection is contraindicated in: •Hyperca lcemia • Neonates (28 days of age or younger) receiving ceftriaxone [see Warnings and Precautions (5.2)] • Hypercalcemia (4) • Neonates (28 days of age or younger) receiving ceftriaxone (4)"],"description_table":["
1,000 mg per 50 mL2,000 mg per 100 mL
Calcium Gluconate20 mg per mL20 mg per mL
Elemental Calcium1.86 mg per mL1.86 mg per mL
Sodium Chloride6.75 mg per mL6.75 mg per mL
Hydrochloric Acid or Sodium HydroxidepH adjusted 6.0 to 8.2
"],"drug_interactions":["7 DRUG INTERACTIONS • Cardiac Glycoside : Synergistic arrhythmias may occur if calcium and cardiac glycosides are administered together. (7.1) • Calcium Channel Blockers : Administration of calcium may reduce the response. (7.2) • Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. Monitor plasma calcium concentrations in patients taking these drugs concurrently. (7.3) 7.1 Cardiac Glycosides Hypercalcemia increases the risk of digoxin toxicity, while digoxin may be therapeutically ineffective in the presence of hypocalcemia. Synergistic arrhythmias may occur if calcium and cardiac glycosides are administered together. Avoid administration of Calcium Gluconate in Sodium Chloride Injection in patients receiving cardiac glycosides; if considered necessary, administer Calcium Gluconate in Sodium Chloride Injection slowly in small amounts and monitor ECG closely during administration. 7.2 Calcium Channel Blockers Administration of calcium may reduce the response to calcium channel blockers. 7.3 Drugs that may cause Hypercalcemia Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. Monitor plasma calcium concentrations in patients taking these drugs concurrently."],"how_supplied_table":["
Total Strength per Total VolumeStrength per mL24 single-dose bags NDCBag and Overwrap NDC
1,000 mg per 50 mL 20 mg/mL44567-620-84*44567-620-02
2,000 mg per 100 mL20 mg/mL44567-621-8444567-621-02
"],"mechanism_of_action":["12.1 Mechanism of Action Intravenous administration of calcium gluconate increases serum ionized calcium level. Calcium gluconate dissociates into ionized calcium in plasma. Ionized calcium and gluconate are constituents of body fluids."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Intravenous administration of calcium gluconate increases serum ionized calcium level. Calcium gluconate dissociates into ionized calcium in plasma. Ionized calcium and gluconate are constituents of body fluids. 12.3 Pharmacokinetics Absorption Calcium Gluconate Injection is 100% bioavailable following intravenous injection. Metabolism Calcium itself does not undergo direct metabolism. The release of ionized calcium from intravenous administration of calcium gluconate is direct and does not seem to be affected by the first pass through the liver. Distribution Calcium in the body is distributed mainly in skeleton (99%). Only 1% of the total body calcium is distributed within the extracellular fluids and soft tissues. About 50% of total serum calcium is in the ionized form and represents the biologically active part. 8% to 10% serum calcium is bound to organic and inorganic acid and approximately 40% is protein-bound (primarily to albumin). Elimination Studies have shown a relationship between urinary calcium excretion and the intravenous administration of calcium gluconate, with a significant increase in urinary calcium excretion observed after the intravenous administration of calcium gluconate."],"indications_and_usage":["1 INDICATIONS AND USAGE Calcium Gluconate in Sodium Chloride Injection is indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia. Limitations of Use The safety of Calcium Gluconate in Sodium Chloride Injection for long term use has not been established. • Calcium Gluconate in Sodium Chloride Injection is a form of calcium indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia. (1) • Limitations of Use: The safety of Calcium Gluconate Injection for long term use has not been established. (1)"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Arrhythmias with Concomitant Cardiac Glycoside Use: If concomitant therapy is necessary, Calcium Gluconate in Sodium Chloride Injection should be given slowly in small amounts and close ECG monitoring is recommended (5.1) • End-Organ Damage due to Intravascular Ceftriaxone-Calcium Precipitates: Concurrent use of intravenous ceftriaxone may cause life-threatening precipitates. Do not administer ceftriaxone simultaneously with Calcium Gluconate in Sodium Chloride Injection via a Y-site in any age group. Cases of fatal outcomes in neonates have occurred. (4, 5.2) • Tissue Necrosis and Calcinosis: Calcinosis cutis can occur with or without extravasation of Calcium Gluconate in Sodium Chloride Injection. Tissue necrosis, ulceration, and secondary infection are the most serious complications. If extravasation occurs or clinical manifestations of calcinosis cutis are noted, immediately discontinue intravenous administration at that site and treat as needed. (5.3) • Hypotension, Bradycardia, and Cardiac Arrhythmias with Rapid Administration: To avoid adverse reactions that may follow rapid intravenous administration, Calcium Gluconate in Sodium Chloride Injection should be infused slowly, with careful ECG monitoring for cardiac arrhythmias. (5.4) • Aluminum Toxicity: This product contains aluminum, up to 25 mcg per liter, that may be toxic. (5.5) 5.1 Arrhythmias with Concomitant Cardiac Glycoside Use Cardiac arrhythmias may occur if calcium and cardiac glycosides are administered together. Hypercalcemia increases the risk of digoxin toxicity. Administration of Calcium Gluconate in Sodium Chloride Injection should be avoided in patients receiving cardiac glycosides. If concomitant therapy is necessary, Calcium Gluconate in Sodium Chloride Injection should be given slowly in small amounts and with close ECG monitoring [see Drug Interactions (7.1)] . 5.2 End-Organ Damage due to Intravascular Ceftriaxone-Calcium Precipitates Concomitant use of ceftriaxone and Calcium Gluconate in Sodium Chloride Injection is contraindicated in neonates (28 days of age or younger) due to cases of fatal outcomes in neonates in which a crystalline material was observed in the lungs and kidneys at autopsy after ceftriaxone and calcium were administrated simultaneously through the same intravenous line. Concomitant administration can lead to the formation of ceftriaxone-calcium precipitates that may act as emboli, resulting in vascular spasm or infarction [see Contraindications (4)]. In patients older than 28 days of age, ceftriaxone and Calcium Gluconate in Sodium Chloride Injection may be administered sequentially, provided the infusion lines are thoroughly flushed between infusions with a compatible fluid. Do not administer Ceftriaxone simultaneously with Calcium Gluconate in Sodium Chloride Injection via a Y-site in any age group. 5.3 Tissue Necrosis and Calcinosis Intravenous administration of Calcium Gluconate in Sodium Chloride Injection and local trauma may result in calcinosis cutis due to transient increase in local calcium concentration. Calcinosis cutis can occur with or without extravasation of Calcium Gluconate in Sodium Chloride Injection, is characterized by abnormal dermal deposits of calcium salts, and clinically manifests as papules, plaques, or nodules that may be associated with erythema, swelling, or induration. Tissue necrosis, ulceration, and secondary infection are the most serious complications. If extravasation occurs or clinical manifestations of calcinosis cutis are noted, immediately discontinue intravenous administration at that site and treat as needed. 5.4 Hypotension, Bradycardia, and Cardiac Arrhythmias with Rapid Administration Rapid injection of Calcium Gluconate in Sodium Chloride Injection may cause vasodilation, decreased blood pressure, bradycardia, cardiac arrhythmias, syncope and cardiac arrest. To avoid adverse reactions that may follow rapid intravenous administration, Calcium Gluconate in Sodium Chloride Injection should be infused slowly. If rapid intravenous bolus of Calcium Gluconate Injection is required, the rate of intravenous administration should not exceed 200 mg/minute in adults and 100 mg/minute in pediatric patients and ECG monitoring during administration is recommended [see Dosage and Administration (2.1)] . 5.5 Aluminum Toxicity Calcium Gluconate in Sodium Chloride Injection contains aluminum, up to 25 mcg per liter, that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 mcg/kg/day to 5 mcg/kg/day accumulate aluminum levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals have not been conducted to evaluate the carcinogenic potential of Calcium Gluconate in Sodium Chloride Injection. Calcium gluconate was not mutagenic with or without metabolic activation in the Ames test with Salmonella typhimurium (strains TA-1535, TA-1537, and TA-1538) or Saccharomyces cerevisiae (Strain D4). Fertility studies in animals have not been conducted with calcium gluconate administered by the intravenous route."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Inform patients of the risks associated with infusion of Calcium Gluconate in Sodium Chloride Injection including local tissue inflammation, local necrosis and calcinosis. [see Warnings and Precautions (5.3)] . Manufactured for: WG Critical Care, LLC Paramus, NJ 07652 Made in Switzerland U.S. Patent Numbers 10,342,813 and 10,130,646 Novaplus is a registered trademark of Vizient, Inc. novapluse logo image"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION • Administer intravenously (bolus or continuous infusion) via a secure intravenous line (2.1) • See Full Prescribing Information (FPI) for administration rates, and appropriate monitoring (2.1) • Do not dilute Calcium Gluconate in Sodium Chloride Injection prior to use. Any unused portion should be discarded (2.1) • Individualize the dose within the recommended range in adults and pediatric patients depending on the severity of symptoms of hypocalcemia, the serum calcium level, and the acuity of onset of hypocalcemia. See Table 1 in the FPI for dosing recommendations in mg of calcium gluconate for neonates, pediatric and adult patients. (2.2) • Measure serum calcium during intermittent infusions every 4 to 6 hours and during continuous infusion every 1 to 4 hours. (2.3) • Calcium Gluconate Injection is not physically compatible with fluids containing phosphate or bicarbonate. Precipitation may result if mixed. See FPI for all drug incompatibilities. (2.5) 2.1 Important Administration Instructions See Table 1 for amounts of elemental calcium in Calcium Gluconate in Sodium Chloride Injection. Table 1. Amounts of Calcium Gluconate and Elemental Calcium Total Strength per Total Volume Strength per mL Elemental Calcium (mg) per mL Elemental Calcium (mEq) per mL Total Amount of Elemental Calcium (mg) per Total Volume Total Amount of Elemental Calcium (mEq) per Total Volume 1,000 mg per 50 mL 20 mg/mL 1.86 mg 0.093 mEq 93 mg per 50 mL 4.65 mEq per 50 mL 1,000 mg per 100 mL 10 mg/mL 0.93 mg 0.0465 mEq 93 mg per 100 mL 4.65 mEq per 100 mL 2,000 mg per 100 mL 20 mg/mL 1.86 mg 0.093 mEq 186 mg per 100 mL 9.3 mEq per 100 mL • Do not dilute Calcium Gluconate in Sodium Chloride Injection prior to use. Any unused portion should be discarded. • Inspect Calcium Gluconate in Sodium Chloride Injection visually prior to administration. The solution should appear clear and colorless. Do not administer if there is particulate matter or discoloration. • Administer Calcium Gluconate in Sodium Chloride Injection intravenously via a secure intravenous line to avoid calcinosis cutis and tissue necrosis [see Warnings and Precautions (5.3)]. Administer Calcium Gluconate in Sodium Chloride Injection by continuous infusion at the rate recommended in Table 1 [see Dosage and Administration (2.2)] and monitor patients, vitals, calcium and ECG during the infusion [see Warnings and Precautions (5.4)] . 2.2 Recommended Dosage Individualize the dose of Calcium Gluconate in Sodium Chloride Injection within the recommended range depending on the severity of symptoms of hypocalcemia, the serum calcium level, and the acuity of onset of hypocalcemia. Table 2 provides dosing recommendations for Calcium Gluconate in Sodium Chloride Injection in mg of calcium gluconate for neonates, pediatric and adult patients. Table 2. Dosing Recommendations in mg of Calcium Gluconate for Neonate, Pediatric, and Adult Patients PatientPopulation Initial Dose Subsequent Doses (if needed) Bolus Continuous Infusion Neonate (less than1 month to 1 month) 100 mg/kg to 200 mg/kg 100 mg/kg to 200 mg/kg every 6 hours Initiate at 17 mg/kg/hour to 33 mg/kg/hour Pediatric (greater than 1 month to less than 17 years) 29 mg/kg to 60 mg/kg 29 mg/kg to 60 mg/kg every 6 hours Initiate at 8 mg/kg/hour to 13 mg/kg/hour Adult (17 years and greater) 1,000 mg to 2,000 mg 1,000 mg to 2,000 mg every 6 hours Initiate at 5.4 mg/kg/hour to 21.5 mg/kg/hour For bolus administration, DO NOT exceed an infusion rate of: •200 mg/minute in adult patients •100 mg/minute in pediatric patients For continuous infusions, adjust rate as needed based on serum calcium levels 2.3 Serum Calcium Monitoring Measure serum calcium every 4 to 6 hours during intermittent infusions with Calcium Gluconate in Sodium Chloride Injection and measure serum calcium every 1 to 4 hours during continuous infusion. 2.4 Dosage in Renal Impairment For patients with renal impairment, initiate Calcium Gluconate in Sodium Chloride Injection at the lowest dose of the recommended dose ranges for all age groups and monitor serum calcium levels every 4 hours. 2.5 Drug Incompatibilities • Do not mix Calcium Gluconate in Sodium Chloride Injection with ceftriaxone. Concurrent use of intravenous ceftriaxone and Calcium Gluconate in Sodium Chloride Injection can lead to the formation of ceftriaxone-calcium precipitates. Concomitant use of ceftriaxone and intravenous calcium-containing products is contraindicated in neonates (28 days of age or younger) [see Contraindications (4)] . In patients older than 28 days of age, ceftriaxone and calcium-containing products may be administered sequentially, provided the infusion lines are thoroughly flushed between infusions with a compatible fluid. Ceftriaxone must not be administered simultaneously with intravenous calcium-containing solutions via a Y-site in any age group [see Warnings and Precautions (5.2), Drug Interactions (7.3)]. • Do not mix Calcium Gluconate in Sodium Chloride Injection with fluids containing bicarbonate or phosphate. Calcium Gluconate Injection is not physically compatible with fluids containing phosphate or bicarbonate. Precipitation may result if mixed. • Do not mix Calcium Gluconate in Sodium Chloride Injection with minocycline injection. Calcium complexes minocycline rendering it inactive."],"spl_product_data_elements":["Calcium Gluconate in Sodium Chloride Calcium Gluconate CALCIUM GLUCONATE MONOHYDRATE CALCIUM CATION CALCIUM SACCHARATE HYDROCHLORIC ACID SODIUM HYDROXIDE SODIUM CHLORIDE NATURAL LATEX RUBBER Calcium Gluconate in Sodium Chloride Calcium Gluconate CALCIUM GLUCONATE MONOHYDRATE CALCIUM CATION CALCIUM SACCHARATE HYDROCHLORIC ACID SODIUM HYDROXIDE SODIUM CHLORIDE NATURAL LATEX RUBBER"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Calcium Gluconate in Sodium Chloride Injection is a clear, colorless solution available as: Injection: • Calcium gluconate 1,000 mg per 50 mL (20 mg/mL) single-dose bag • Calcium gluconate 2,000 mg per 100 mL (20 mg/mL) single-dose bag Injection: • Calcium gluconate 1,000 mg per 50 mL (20 mg/mL) single-dose bag (3) • Calcium gluconate 2,000 mg per 100 mL (20 mg/mL) single-dose bag (3)"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS • Geriatric use : Dosing in elderly patients should be cautious, usually starting at the low end of the dosage range. (8.5) • Renal impairment: Initiate with the lower limit of the dosage range and monitor serum calcium levels every 4 hours. (8.6, 2.4) 8.1 Pregnancy Risk summary Limited available data with Calcium Gluconate Injection use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. There are risks to the mother and the fetus associated with hypocalcemia in pregnancy [see Clinical Considerations] . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Disease-associated maternal risk Maternal hypocalcemia can result in an increased rate of spontaneous abortion, premature and dysfunctional labor, and possibly preeclampsia. Fetal/Neonatal adverse reactions Infants born to mothers with hypocalcemia can have associated fetal and neonatal hyperparathyroidism, which in turn can cause fetal and neonatal skeletal demineralization, subperiosteal bone resorption, osteitis fibrosa cystica and neonatal seizures. Infants born to mothers with hypocalcemia should be carefully monitored for signs of hypocalcemia or hypercalcemia, including neuromuscular irritability, apnea, cyanosis and cardiac rhythm disorders. 8.2 Lactation Risk summary Calcium is present in human milk as a natural component of human milk. It is not known whether intravenous administration of Calcium Gluconate in Sodium Chloride Injection can alter calcium concentration in human milk. There are no data on the effects of Calcium Gluconate Injection on the breastfed infant, or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Calcium Gluconate in Sodium Chloride Injection and any potential adverse effects on the breastfed child from Calcium Gluconate in Sodium Chloride Injection or from the underlying maternal condition. 8.4 Pediatric Use The safety and effectiveness of Calcium Gluconate in Sodium Chloride Injection have been established in pediatric patients for the treatment of acute, symptomatic hypocalcemia. Pediatric approval for Calcium Gluconate in Sodium Chloride Injection, including doses, is not based on adequate and well-controlled clinical studies. Safety and dosing recommendations in pediatric patients are based on published literature and clinical experience [see Dosage and Administration (2.2)] . Concomitant use of ceftriaxone and Calcium Gluconate in Sodium Chloride Injection is contraindicated in neonates (28 days of age or younger) due to reports of fatal outcomes associated with the presence of lung and kidney ceftriaxone-calcium precipitates. In patients older than 28 days of age, ceftriaxone and Calcium Gluconate Injection may be administered sequentially, provided the infusion lines are thoroughly flushed between infusions with a compatible fluid [ see Contraindications (4) and Warnings and Precautions (5.2)] . This product contains up to 25 mcg/L aluminum which may be toxic, particularly for premature neonates due to immature renal function. Parenteral administration of aluminum greater than 4 mcg/kg/day to 5 mcg/kg/day is associated with central nervous system and bone toxicity [see Warnings and Precautions (5.5)] . 8.5 Geriatric Use In general dose selection for an elderly patient should start at the lowest dose of the recommended dose range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. 8.6 Renal Impairment For patients with renal impairment, initiate Calcium Gluconate in Sodium Chloride Injection at the lowest dose of the recommended dose ranges across all age groups. Monitor serum calcium levels every 4 hours [see Dosage and Administration (2.4)]. 8.7 Hepatic Impairment Hepatic function does not impact the availability of ionized calcium after calcium gluconate intravenous administration. Dose adjustment in hepatically impaired patients may not be necessary."],"dosage_and_administration_table":["
Total Strength per Total VolumeStrength per mLElemental Calcium (mg) per mLElemental Calcium (mEq) per mLTotal Amount of Elemental Calcium (mg) per Total VolumeTotal Amount of Elemental Calcium (mEq) per Total Volume
1,000 mg per 50 mL 20 mg/mL1.86 mg0.093 mEq93 mg per 50 mL4.65 mEq per 50 mL
1,000 mg per 100 mL10 mg/mL0.93 mg0.0465 mEq93 mg per 100 mL4.65 mEq per 100 mL
2,000 mg per 100 mL20 mg/mL1.86 mg0.093 mEq186 mg per 100 mL9.3 mEq per 100 mL
","•200 mg/minute in adult patients•100 mg/minute in pediatric patients For continuous infusions, adjust rate as needed based on serum calcium levels
PatientPopulationInitial DoseSubsequent Doses (if needed)
BolusContinuous Infusion
Neonate (less than1 month to 1 month)100 mg/kg to 200 mg/kg100 mg/kg to 200 mg/kg every 6 hoursInitiate at 17 mg/kg/hour to 33 mg/kg/hour
Pediatric (greater than 1 month to less than 17 years)29 mg/kg to 60 mg/kg29 mg/kg to 60 mg/kg every 6 hoursInitiate at 8 mg/kg/hour to 13 mg/kg/hour
Adult (17 years and greater)1,000 mg to 2,000 mg1,000 mg to 2,000 mg every 6 hoursInitiate at 5.4 mg/kg/hour to 21.5 mg/kg/hour
For bolus administration, DO NOT exceed an infusion rate of:
"],"package_label_principal_display_panel":["PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 44567-620-02 Novaplus Calcium Gluconate in Sodium Chloride Injection 1,000 mg per 50 mL (20 mg/mL) Novaplus Cal Gluc 1,000 mg per 50 mL Bag image","Package/Label Display Panel NDC 44567-621-02 Novaplus Calcium Gluconate in Sodium Chloride Injection 2,000 mg per 100 mL (20 mg/mL) Novaplus Cal Gluc 2,000 mg per 100 mL Bag image"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals have not been conducted to evaluate the carcinogenic potential of Calcium Gluconate in Sodium Chloride Injection. Calcium gluconate was not mutagenic with or without metabolic activation in the Ames test with Salmonella typhimurium (strains TA-1535, TA-1537, and TA-1538) or Saccharomyces cerevisiae (Strain D4). Fertility studies in animals have not been conducted with calcium gluconate administered by the intravenous route."]},"tags":[{"label":"calcium gluconate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A12AA03","category":"atc"},{"label":"Topical","category":"route"},{"label":"Intravenous","category":"route"},{"label":"Oral","category":"route"},{"label":"Gel","category":"form"},{"label":"Injection","category":"form"},{"label":"Liquid","category":"form"},{"label":"Generic Available","category":"availability"},{"label":"Active","category":"status"},{"label":"Hypocalcemia","category":"indication"},{"label":"Hypocalcemic tetany","category":"indication"},{"label":"Osteoporosis","category":"indication"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"2061 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"1636 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"1626 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"1522 reports"},{"date":"","signal":"RHEUMATOID ARTHRITIS","source":"FDA FAERS","actionTaken":"1337 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"1309 reports"},{"date":"","signal":"ALOPECIA","source":"FDA FAERS","actionTaken":"1281 reports"},{"date":"","signal":"PEMPHIGUS","source":"FDA FAERS","actionTaken":"1204 reports"},{"date":"","signal":"PSORIATIC ARTHROPATHY","source":"FDA FAERS","actionTaken":"1200 reports"},{"date":"","signal":"ARTHROPATHY","source":"FDA FAERS","actionTaken":"1196 reports"}],"commonSideEffects":[{"effect":"local soft tissue inflammation","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"necrosis","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"calcification","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"vasodilation","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"decreased blood pressure","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"bradycardia","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"cardiac arrhythmia","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"syncope","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"cardiac arrest","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"calcinosis cutis","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3}],"contraindications":["Acute erosive gastritis","Acute nephropathy","Agoraphobia","Alcoholism","Anemia","Anemia due to enzyme deficiency","Arteriosclerosis obliterans","Breastfeeding (mother)","Conduction disorder of the heart","Constipation","Dehydration","Disease of liver","End stage renal disease","Factor II deficiency","Gastrointestinal hemorrhage","Gastrointestinal ulcer","Gout","Heart disease","Hemophilia","Hepatic failure","Humoral hypercalcemia of malignancy","Hypercalcemia","Hypercalciuria","Hyperparathyroidism","Hyperphosphatemia"],"specialPopulations":{"Pregnancy":"Limited available data with Calcium Gluconate Injection use in pregnant women are insufficient to inform drug associated risk of adverse developmental outcomes. There are risks to the mother and the fetus associated with hypocalcemia in pregnancy. Infants born to mothers with hypocalcemia can have associated fetal and neonatal hyperparathyroidism, which in turn can cause fetal and neonatal skeletal demineralization, subperiosteal bone resorption, osteitis fibrosa cystica and neonatal seizures.","Geriatric use":"In general dose selection for an elderly patient should start at the lowest dose of the recommended dose range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.","Paediatric use":"The safety and effectiveness of Calcium Gluconate in Sodium Chloride Injection have been established in pediatric patients for the treatment of acute, symptomatic hypocalcemia. Pediatric approval for Calcium Gluconate in Sodium Chloride Injection, including doses, is not based on adequate and well-controlled clinical studies. Safety and dosing recommendations in pediatric patients are based on published literature and clinical experience."}},"trials":[],"aliases":[],"patents":[{"applNo":"N208418","source":"FDA Orange Book","status":"Active","expires":"Jul 25, 2037","useCode":"","territory":"US","drugProduct":true,"patentNumber":"10130646","drugSubstance":false},{"type":"Formulation","number":"10342813","applicant":"HQ SPECIALTY PHARMA CORP","territory":"US","tradeName":"CALCIUM GLUCONATE IN SODIUM CHLORIDE","expiryDate":"2037-07-25"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CALCIUM GLUCONATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:02:33.081142+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:02:33.081043+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Calcium Gluconate","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:02:40.122997+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:02:38.613259+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:02:31.607435+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CALCIUM GLUCONATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:02:38.978151+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:02:30.078959+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:02:30.078983+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:02:49.128973+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action Intravenous administration of calcium gluconate increases serum ionized calcium level. Calcium gluconate dissociates into ionized calcium in plasma. Ionized calcium and gluconate are constituents of body fluids.","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:03:02.775014+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2106119/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:02:39.791980+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS The following serious adverse reactions are also described elsewhere in the labeling: • Arrhythmias with Concomitant Cardiac Glycoside Use [see Warnings and Precautions (5.1)] • End-Organ Damage due to Intravascular Ceftriaxone-Calcium Precipitates [see Warnings and Precautions (5.2)] • Tissue Necrosis and Calcinosis [see Warnings and Precautions (5.3)] • Hypotension, Bradycardia, and Cardiac Arrhythmias [see Warnings and Precautions (5.4)] • Aluminum toxicity [see Warnings a","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:03:05.441948+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA210906","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:02:30.078986+00:00"}},"allNames":["calcium gluconate","calciofon","Calcium D-gluconate","calcium gluconate monohydrate"],"offLabel":[],"synonyms":["calcium gluconate","calciofon","Calcium D-gluconate","calcium gluconate monohydrate"],"timeline":[{"date":"2021-06-04","type":"positive","source":"FDA Orange Book","milestone":"Calcium Gluconate In Sodium Chloride approved — 1GM/100ML (10MG/ML)"},{"date":"2024-04-30","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 4 manufacturers approved"}],"aiSummary":"Calcium Gluconate is a small molecule calcium salt used to treat hypocalcemia, hypocalcemic tetany, and osteoporosis. It is a generic medication, with multiple manufacturers, and is currently owned by Fresenius Kabi USA. The exact mechanism of action is not well-documented, but it is believed to work by replenishing calcium stores in the body. Calcium Gluconate is not a patented medication, indicating it is no longer under exclusive patent protection. Key safety considerations include potential cardiac complications and interactions with other medications.","brandName":"Calcium Gluconate","ecosystem":[{"indication":"Hypocalcemia","otherDrugs":[{"name":"calcifediol","slug":"calcifediol","company":""},{"name":"calcitriol","slug":"calcitriol","company":"Validus Pharms"},{"name":"calcium acetate","slug":"calcium-acetate","company":"B Braun"},{"name":"calcium carbonate","slug":"calcium-carbonate","company":"Mcneil Cons"}],"globalPrevalence":null},{"indication":"Hypocalcemic tetany","otherDrugs":[{"name":"calcium acetate","slug":"calcium-acetate","company":"B Braun"},{"name":"calcium chloride","slug":"calcium-chloride","company":"Baxter Hlthcare"},{"name":"calcium glucoheptonate","slug":"calcium-glucoheptonate","company":"Abbott"},{"name":"calcium glycerylphosphate","slug":"calcium-glycerylphosphate","company":""}],"globalPrevalence":null},{"indication":"Osteoporosis","otherDrugs":[{"name":"abaloparatide","slug":"abaloparatide","company":"Radius Health Inc"},{"name":"calcium citrate","slug":"calcium-citrate","company":""},{"name":"calcium phosphate","slug":"calcium-phosphate","company":""},{"name":"colecalciferol","slug":"colecalciferol","company":"Sandoz"}],"globalPrevalence":200000000}],"mechanism":{"novelty":"First-in-class","modality":"Small Molecule","drugClass":"calcium gluconate","explanation":"When calcium gluconate is given intravenously, it dissociates into ionized calcium in the plasma. This increase in ionized calcium levels can affect various physiological processes that depend on calcium.","oneSentence":"Calcium gluconate increases serum ionized calcium levels when administered intravenously.","technicalDetail":"Calcium gluconate dissociates into ionized calcium and gluconate in plasma. The ionized calcium is a constituent of body fluids and can influence cellular functions and signaling pathways."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Calcium_gluconate","title":"Calcium gluconate","extract":"Calcium gluconate is the calcium salt of gluconic acid and is used as a mineral supplement and medication. As a medication it is used by injection into a vein to treat low blood calcium, high blood potassium, and magnesium toxicity. Supplementation is generally only required when there is not enough calcium in the diet. Supplementation may be done to treat or prevent osteoporosis or rickets. It can also be taken by mouth but is not recommended for injection into a muscle.","wiki_society_and_culture":"==Society and culture==\n\n* Shortages of medical calcium gluconate were reported in November 2012 and November 2015 in the United States.\n* Historically, intravenous calcium gluconate was used as an antidote for black widow spider envenomation, often in conjunction with muscle relaxants. This therapy, however, has since been shown to be ineffective.\n"},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4348","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CALCIUM%20GLUCONATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CALCIUM GLUCONATE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Calcium_gluconate","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T09:07:36.877433","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T00:03:06.982765+00:00","fieldsConflicting":10,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"calcium phosphate","drugSlug":"calcium-phosphate","fdaApproval":"","relationship":"same-class"},{"drugName":"calcium carbonate","drugSlug":"calcium-carbonate","fdaApproval":"2000-10-16","relationship":"same-class"},{"drugName":"calcium chloride","drugSlug":"calcium-chloride","fdaApproval":"1971-03-22","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"calcium glycerylphosphate","drugSlug":"calcium-glycerylphosphate","fdaApproval":"","relationship":"same-class"},{"drugName":"calcium glucoheptonate","drugSlug":"calcium-glucoheptonate","fdaApproval":"1972-12-04","relationship":"same-class"},{"drugName":"calcium citrate","drugSlug":"calcium-citrate","fdaApproval":"","relationship":"same-class"}],"genericName":"calcium gluconate","indications":{"approved":[{"name":"Hypocalcemia","source":"DrugCentral","snomedId":5291005,"regulator":"FDA","eligibility":"Adults and pediatric patients with hypocalcemia"},{"name":"Hypocalcemic tetany","source":"DrugCentral","snomedId":190869004,"regulator":"FDA","eligibility":"Adults and pediatric patients with hypocalcemic tetany"},{"name":"Osteoporosis","source":"DrugCentral","snomedId":64859006,"regulator":"FDA","eligibility":"Adults with osteoporosis","usPrevalence":10000000,"globalPrevalence":200000000,"prevalenceMethod":"curated","prevalenceSource":"IOF, 2023"}],"offLabel":[],"pipeline":[]},"currentOwner":"Fresenius Kabi Usa","drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"calcium-phosphate","brandName":"calcium phosphate","genericName":"calcium phosphate","approvalYear":"","relationship":"same-class"},{"drugId":"calcium-carbonate","brandName":"calcium carbonate","genericName":"calcium carbonate","approvalYear":"2000","relationship":"same-class"},{"drugId":"calcium-chloride","brandName":"calcium chloride","genericName":"calcium chloride","approvalYear":"1971","relationship":"same-class"},{"drugId":"calcium-glycerylphosphate","brandName":"calcium glycerylphosphate","genericName":"calcium glycerylphosphate","approvalYear":"","relationship":"same-class"},{"drugId":"calcium-glucoheptonate","brandName":"calcium glucoheptonate","genericName":"calcium glucoheptonate","approvalYear":"1972","relationship":"same-class"},{"drugId":"calcium-citrate","brandName":"calcium citrate","genericName":"calcium citrate","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07223671","phase":"PHASE1","title":"Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2025-12-31","conditions":["Healthy Volunteers"],"enrollment":30,"completionDate":"2026-03-19"},{"nctId":"NCT07495605","phase":"NA","title":"Effect of 1% Melatonin Gel Versus Calcium Hydroxide as an Intracanal Medicament on the Intensity of Postoperative Pain, Bacterial Load Reduction and Periapical MMP-9 Levels in Patients With Necrotic Pulp.","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-03-22","conditions":["Intensity of Postoperative Pain, Bacterial Load Reduction and Periapical MMP-9 Levels in Patients With Necrotic Pulp"],"enrollment":50,"completionDate":"2027-12"},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":["Acute Leukemia of Ambiguous Lineage","B Acute Lymphoblastic Leukemia"],"enrollment":153,"completionDate":"2028-12-31"},{"nctId":"NCT04040634","phase":"NA","title":"Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2019-08-08","conditions":["Diabetes Mellitus","High Blood Pressure","Cardiovascular Diseases","Cognitive Impairment"],"enrollment":9476,"completionDate":"2026-05-31"},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Down Syndrome"],"enrollment":6720,"completionDate":"2027-09-30"},{"nctId":"NCT03798678","phase":"PHASE1","title":"CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-08","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":36,"completionDate":"2026-06-30"},{"nctId":"NCT06166849","phase":"NA","title":"Clinical Evaluation of an Experimental Remineralization Product","status":"COMPLETED","sponsor":"Ivoclar Vivadent AG","startDate":"2023-03-28","conditions":["White Spot Lesion"],"enrollment":43,"completionDate":"2025-03-11"},{"nctId":"NCT06169215","phase":"PHASE2","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-23","conditions":["Multiple Myeloma"],"enrollment":70,"completionDate":"2026-09-30"},{"nctId":"NCT07463807","phase":"PHASE1,PHASE2","title":"Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-26","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":162,"completionDate":"2026-08-31"},{"nctId":"NCT06899061","phase":"PHASE1","title":"Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-25","conditions":["Advanced Solid Malignancies"],"enrollment":41,"completionDate":"2026-04-30"},{"nctId":"NCT07196683","phase":"NA","title":"Regenerative Potentials of Mature Mandibular Molars With Symptomatic Irreversible Pulpitis Enhanced With Different Scaffolds","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-07-01","conditions":["Symptomatic Irreversible Pulpitis (SIP)"],"enrollment":36,"completionDate":"2027-11-01"},{"nctId":"NCT06867068","phase":"PHASE1","title":"Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2016-10-04","conditions":["Anesthesia","Tooth Extraction"],"enrollment":73,"completionDate":"2024-06-10"},{"nctId":"NCT07494136","phase":"PHASE4","title":"Dose Dependent Steroid Injections","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-05","conditions":["Lumbar Radiculopathy","Sciatica","Back Pain With Radiation"],"enrollment":150,"completionDate":"2027-05"},{"nctId":"NCT02997228","phase":"PHASE3","title":"Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-19","conditions":["Metastatic Colorectal Adenocarcinoma","Stage IV Colorectal Cancer AJCC v7"],"enrollment":120,"completionDate":"2027-06-01"},{"nctId":"NCT07396688","phase":"NA","title":"Comparative Evaluation of the Effects of Calcium Hydroxide and BIO-C Temp Medicaments on Postoperative Pain in Patients Undergoing Endodontic Treatment: a Clinical Study","status":"RECRUITING","sponsor":"Ankara University","startDate":"2026-03-25","conditions":["Postoperative Pain","Medicaments Substances in Therapeutic Use","Calcium Hydroxide","Root Canal Retreatment"],"enrollment":60,"completionDate":"2026-04-15"},{"nctId":"NCT05564403","phase":"PHASE2","title":"Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-09","conditions":["Advanced Biliary Tract Carcinoma","Advanced Gallbladder Carcinoma","Advanced Intrahepatic Cholangiocarcinoma","Recurrent Biliary Tract Carcinoma","Recurrent Gallbladder Carcinoma","Recurrent Intrahepatic Cholangiocarcinoma","Stage III Distal Bile Duct Cancer AJCC v8","Stage III Gallbladder Cancer AJCC v8","Stage III Hilar Cholangiocarcinoma AJCC v8","Stage III Intrahepatic Cholangiocarcinoma AJCC v8","Stage IV Distal Bile Duct Cancer AJCC v8","Stage IV Gallbladder Cancer AJCC v8","Stage IV Hilar Cholangiocarcinoma AJCC v8","Stage IV Intrahepatic Cholangiocarcinoma AJCC v8","Unresectable Biliary Tract Carcinoma","Unresectable Gallbladder Carcinoma","Unresectable Intrahepatic Cholangiocarcinoma"],"enrollment":66,"completionDate":"2026-05-01"},{"nctId":"NCT07244991","phase":"NA","title":"Effect of MI Paste Plus™ on Streptococcus Mutans and White Spot Lesions in Fixed Orthodontics","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2026-01-04","conditions":["Dental Caries","Streptococcus Mutans","Tooth Demineralization","Orthodontic Appliances, Fixed"],"enrollment":200,"completionDate":"2027-11"},{"nctId":"NCT05933499","phase":"PHASE2","title":"Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-11-05","conditions":["Obesity"],"enrollment":63,"completionDate":"2029-03-31"},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":["Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Adult L1 Acute Lymphoblastic Leukemia","Adult L2 Acute Lymphoblastic Leukemia","Adult T Acute Lymphoblastic Leukemia","Recurrent Adult Acute Lymphoblastic Leukemia"],"enrollment":97,"completionDate":"2027-01-06"},{"nctId":"NCT06696768","phase":"PHASE1","title":"Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-23","conditions":["Metastatic Colorectal Adenocarcinoma","Stage III Colorectal Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8","Unresectable Colorectal Adenocarcinoma"],"enrollment":24,"completionDate":"2026-12-31"},{"nctId":"NCT06948084","phase":"PHASE2","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-29","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":80,"completionDate":"2028-02-28"},{"nctId":"NCT07105930","phase":"NA","title":"Trial to Assess Non-inferiority of an Orbital Atherectomy Only Versus a Calcium-tailored Debulking Approach","status":"RECRUITING","sponsor":"IHF GmbH - Institut für Herzinfarktforschung","startDate":"2025-10-30","conditions":["Orbital Atherectomy"],"enrollment":310,"completionDate":"2027-03"},{"nctId":"NCT06018831","phase":"NA","title":"Urine and Ultrasound Screening for Kidney Disease in Children","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2022-04-12","conditions":["Kidney Diseases","Diagnostic Techniques","Ultrasound","Urinalysis","Child, Only"],"enrollment":13000,"completionDate":"2028-02"},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":["B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1"],"enrollment":348,"completionDate":"2028-07-01"},{"nctId":"NCT04969926","phase":"","title":"Natural History Study of Parathyroid Disorders","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2021-11-30","conditions":["Parathyroid Cancer","Primary Hyperparathyroidism","Pseudohypoparathyroidism","Inheritable Bone Diseases","Multiple Endocrine Neoplasia, Type 1"],"enrollment":3000,"completionDate":"2031-01-22"},{"nctId":"NCT04847453","phase":"PHASE1","title":"Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-03","conditions":["Recurrent AL Amyloidosis","Refractory AL Amyloidosis"],"enrollment":24,"completionDate":"2026-06-30"},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":["Ann Arbor Stage II Mantle Cell Lymphoma","Ann Arbor Stage III Mantle Cell Lymphoma","Ann Arbor Stage IV Mantle Cell Lymphoma"],"enrollment":16,"completionDate":"2027-09-01"},{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":["DS Stage I Multiple Myeloma","DS Stage II Multiple Myeloma","DS Stage III Multiple Myeloma"],"enrollment":525,"completionDate":"2026-09-18"},{"nctId":"NCT04835129","phase":"PHASE2","title":"Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2022-01-10","conditions":["Multiple Myeloma"],"enrollment":28,"completionDate":"2027-06-01"},{"nctId":"NCT07431866","phase":"PHASE1","title":"A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-18","conditions":["Healthy"],"enrollment":39,"completionDate":"2026-06-07"},{"nctId":"NCT05811403","phase":"NA","title":"Epigallocatechin Gallate (EGCG) as a Flushing Agent During Full Pulpotomy in Mature Permanent Molars With Irreversible Pulpitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cairo University","startDate":"2023-07-01","conditions":["Irreversible Pulpitis"],"enrollment":64,"completionDate":"2026-06-30"},{"nctId":"NCT07015242","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-11-06","conditions":["Lymphoma"],"enrollment":65,"completionDate":"2028-12-10"},{"nctId":"NCT03994471","phase":"PHASE3","title":"Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.","status":"RECRUITING","sponsor":"Iperboreal Pharma Srl","startDate":"2022-12-14","conditions":["End Stage Renal Disease"],"enrollment":170,"completionDate":"2027-04-28"},{"nctId":"NCT07491601","phase":"NA","title":"PRESS -PAR: Early Detection and PREvention of Symptomatic postSurgical hypoPARathyroidism After Thyroid Surgery\"","status":"RECRUITING","sponsor":"Nicolas Schlegel","startDate":"2025-01-08","conditions":["Postoperative Hypoparathyroidism","Postsurgical Hypoparathyroidism","Hypoparathyroidism Post-surgical"],"enrollment":336,"completionDate":"2029-12-31"},{"nctId":"NCT05519085","phase":"PHASE3","title":"A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","status":"RECRUITING","sponsor":"Celgene","startDate":"2022-09-20","conditions":["Relapsed or Refractory Multiple Myeloma"],"enrollment":810,"completionDate":"2033-11-30"},{"nctId":"NCT06524921","phase":"NA","title":"Biodentine Pulpotomy vs Metapex Pulpectomy in Primary Molars: Clinical & Radiographic Comparison of Outcomes in Irreversible Pulpitis Cases","status":"COMPLETED","sponsor":"Mohamed Ahmed Hamdi Abo El Yamin","startDate":"2024-10-01","conditions":["Dental Caries"],"enrollment":28,"completionDate":"2025-09-15"},{"nctId":"NCT06235567","phase":"PHASE1,PHASE2","title":"Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking","status":"ENROLLING_BY_INVITATION","sponsor":"Maanasa Indaram, MD","startDate":"2025-04-11","conditions":["Keratoconus"],"enrollment":20,"completionDate":"2026-12"},{"nctId":"NCT04930237","phase":"","title":"RELISTOR's Effects on Opioid-Induced Constipation","status":"WITHDRAWN","sponsor":"Methodist Health System","startDate":"2021-07-01","conditions":["OIC"],"enrollment":0,"completionDate":"2022-04-22"},{"nctId":"NCT04248452","phase":"PHASE3","title":"Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-05-26","conditions":["Clinical Stage IV Esophageal Adenocarcinoma AJCC v8","Clinical Stage IV Gastric Cancer AJCC v8","Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8","Clinical Stage IVA Gastric Cancer AJCC v8","Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8","Clinical Stage IVB Gastric Cancer AJCC v8","Metastatic Esophageal Adenocarcinoma","Metastatic Gastric Adenocarcinoma","Oligometastatic Esophageal Adenocarcinoma","Oligometastatic Gastric Adenocarcinoma","Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IV Gastric Cancer AJCC v8","Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8"],"enrollment":314,"completionDate":"2028-03-31"},{"nctId":"NCT06156293","phase":"NA","title":"Prevention of Insomnia Using a Stepped Care Model in Adults","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2023-12-01","conditions":["Sleep Disturbance"],"enrollment":1016,"completionDate":"2026-12-31"},{"nctId":"NCT03969329","phase":"PHASE3","title":"A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis","status":"RECRUITING","sponsor":"Amgen","startDate":"2019-12-20","conditions":["Secondary Hyperparathyroidism"],"enrollment":24,"completionDate":"2027-06-30"},{"nctId":"NCT07488858","phase":"NA","title":"Thyroidectomy: Microscopic Versus Conventional","status":"COMPLETED","sponsor":"Shahida Islam Medical Complex","startDate":"2025-12-16","conditions":["Thyroid Cancer","Thyroid Surgeries"],"enrollment":74,"completionDate":"2026-03-15"},{"nctId":"NCT01297764","phase":"PHASE1,PHASE2","title":"A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2011-04","conditions":["Multiple Myeloma"],"enrollment":17,"completionDate":"2026-07"},{"nctId":"NCT07477171","phase":"NA","title":"Mineral Trioxide Aggregate (MTA) vs Gutta-Percha for Non-Surgical Endodontic Retreatment in Teeth With Apical Lesions","status":"NOT_YET_RECRUITING","sponsor":"University of Santiago de Compostela","startDate":"2026-03","conditions":["Periapical Diseases","Root Canal Therapy","Mineral Trioxide Aggregate (MTA)"],"enrollment":58,"completionDate":"2027-04"},{"nctId":"NCT04233866","phase":"PHASE2","title":"Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-08-26","conditions":["Metastatic Pancreatic Adenocarcinoma","Stage IV Pancreatic Cancer AJCC v8"],"enrollment":176,"completionDate":"2026-12-31"},{"nctId":"NCT05850091","phase":"PHASE4","title":"Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-12-07","conditions":["Coronary Artery Disease"],"enrollment":200,"completionDate":"2027-05-01"},{"nctId":"NCT07486570","phase":"NA","title":"Anastomotic Leakage Prevention by Endovascular Stenting of the Superior Mesenteric Artery","status":"RECRUITING","sponsor":"Medisch Spectrum Twente","startDate":"2026-02-01","conditions":["Mesenteric Vascular Disease","Colorectal Surgery","Preventive Intervention"],"enrollment":360,"completionDate":"2029-01-01"},{"nctId":"NCT07486453","phase":"PHASE1","title":"Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2026-03-09","conditions":["Primary Hypertension"],"enrollment":60,"completionDate":"2026-04-25"},{"nctId":"NCT02773030","phase":"PHASE1,PHASE2","title":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-10-14","conditions":["Multiple Myeloma"],"enrollment":466,"completionDate":"2028-07-28"},{"nctId":"NCT07216482","phase":"PHASE3","title":"A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-11-11","conditions":["Hyperlipidemia"],"enrollment":975,"completionDate":"2027-03-01"},{"nctId":"NCT05916950","phase":"NA","title":"The THOR IDE Study","status":"RECRUITING","sponsor":"Philips Clinical & Medical Affairs Global","startDate":"2024-10-29","conditions":["Peripheral Artery Disease","Peripheral Artery Stenosis","Peripheral Artery Calcification","PAD"],"enrollment":155,"completionDate":"2027-12"},{"nctId":"NCT06997497","phase":"PHASE3","title":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-16","conditions":["Colon Adenocarcinoma","Rectal Adenocarcinoma"],"enrollment":477,"completionDate":"2030-10-27"},{"nctId":"NCT05722067","phase":"NA","title":"Improvement of Fertilization Rate and Embryo Quality by Treating Calcium Ionophore in IVF Patients: a Sibling Oocyte Control Study","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2023-01-01","conditions":["IVF","Infertility","Artificial Oocyte Activation"],"enrollment":68,"completionDate":"2025-06-30"},{"nctId":"NCT06276270","phase":"NA","title":"Multi-centre, Open-label, First-in-man Study With Mucopad HA","status":"COMPLETED","sponsor":"Contipro Pharma a.s.","startDate":"2023-12-12","conditions":["Oral Mucositis"],"enrollment":50,"completionDate":"2024-11-30"},{"nctId":"NCT06662786","phase":"PHASE3","title":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-18","conditions":["Colorectal Neoplasms"],"enrollment":1000,"completionDate":"2032-01-30"},{"nctId":"NCT07474649","phase":"PHASE3","title":"A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events","status":"NOT_YET_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2026-06-01","conditions":["Coronary Atherosclerosis","Mixed Dyslipidemia","Hypercholesterolemia"],"enrollment":103,"completionDate":"2028-10-02"},{"nctId":"NCT04604301","phase":"NA","title":"Celtra Quatro Crown Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan","startDate":"2020-09-24","conditions":["Fractured Tooth","Decayed Tooth","Unsatisfactory Restoration of Tooth"],"enrollment":48,"completionDate":"2027-11-01"},{"nctId":"NCT06782100","phase":"","title":"MRI Guided Management of Occlusive Peripheral Arterial Disease","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2024-07-01","conditions":["Peripheral Vascular Diseases"],"enrollment":175,"completionDate":"2029-06"},{"nctId":"NCT06673888","phase":"NA","title":"Assessment of Alkasite Restorative Material Versus Resin Modified Glass Ionomer in Class V Cavities: A Clinical Trial","status":"COMPLETED","sponsor":"Cairo University","startDate":"2024-12-01","conditions":["Class V Dental Caries"],"enrollment":50,"completionDate":"2025-12-01"},{"nctId":"NCT07204977","phase":"PHASE1","title":"Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2026-02-02","conditions":["Amyotrophic Lateral Sclerosis","Motor Neuron Disease"],"enrollment":30,"completionDate":"2028-09-30"},{"nctId":"NCT07484035","phase":"NA","title":"Safety and Efficacy Evaluation of an Extensively Hydrolyzed Formula in Infants With Cow's Milk Protein Allergy (CMPA)","status":"NOT_YET_RECRUITING","sponsor":"Heilongjiang Feihe Dairy Co. Ltd.","startDate":"2026-03-05","conditions":["Cow's Milk Protein Allergy (CMPA)"],"enrollment":124,"completionDate":"2026-07-31"},{"nctId":"NCT03704350","phase":"NA","title":"Influence of Obesity on Endogenous Oxalate Synthesis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2019-05-24","conditions":["Kidney Stone"],"enrollment":40,"completionDate":"2026-12-01"},{"nctId":"NCT07480863","phase":"PHASE2","title":"Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-10-01","conditions":["Marginal Zone Lymphoma(MZL)"],"enrollment":65,"completionDate":"2029-10-02"},{"nctId":"NCT04661540","phase":"PHASE2","title":"A Study of Auxora in Patients With Critical COVID-19 Pneumonia","status":"TERMINATED","sponsor":"CalciMedica, Inc.","startDate":"2021-03-02","conditions":["Pneumonia"],"enrollment":10,"completionDate":"2021-12-21"},{"nctId":"NCT02491632","phase":"PHASE2,PHASE3","title":"Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-08-13","conditions":["Advanced Malignant Neoplasm","Fatigue","Metastatic Malignant Neoplasm","Recurrent Malignant Neoplasm","Refractory Malignant Neoplasm"],"enrollment":90,"completionDate":"2026-12-31"},{"nctId":"NCT04143711","phase":"PHASE1,PHASE2","title":"Study of DF1001 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Dragonfly Therapeutics","startDate":"2019-11-11","conditions":["Solid Tumor, Adult"],"enrollment":270,"completionDate":"2025-12-05"},{"nctId":"NCT03301454","phase":"PHASE2","title":"Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2018-08-20","conditions":["Esophageal Cancer, Squamous Cell"],"enrollment":15,"completionDate":"2022-07-05"},{"nctId":"NCT07239739","phase":"NA","title":"Comparing Two Medicines for Healing Jaw Bone Infections After Root Canal Treatment","status":"NOT_YET_RECRUITING","sponsor":"Faiz ur rahman","startDate":"2026-06-15","conditions":["Periapical Lesion","Periapical Periodontitis"],"enrollment":62,"completionDate":"2026-12-15"},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":["Clonal Cytopenia of Undetermined Significance","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Hodgkin Lymphoma","Recurrent Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Lymphoma","Chronic Myelomonocytic Leukemia"],"enrollment":80,"completionDate":"2033-11-02"},{"nctId":"NCT06013722","phase":"NA","title":"Strategy for Unstable Coronary Plaque in Patients Presenting to Emergency Department for Chest Pain Suspected of Coronary Artery Disease","status":"RECRUITING","sponsor":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","startDate":"2024-03-18","conditions":["Atherosclerosis"],"enrollment":250,"completionDate":"2028-03"},{"nctId":"NCT07300280","phase":"PHASE1","title":"A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-29","conditions":["Healthy"],"enrollment":60,"completionDate":"2026-07-22"},{"nctId":"NCT07385781","phase":"","title":"Psychosomatic Symptoms in Patients With Myofascial Pain and Temporomandibular Joint Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"Bahria University","startDate":"2026-03-01","conditions":["Psychosomatic Symptoms","Temporomandibular Disorder (TMD)"],"enrollment":300,"completionDate":"2026-08-30"},{"nctId":"NCT05272826","phase":"PHASE2","title":"Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients","status":"RECRUITING","sponsor":"Canadian Myeloma Research Group","startDate":"2024-12-12","conditions":["Multiple Myeloma"],"enrollment":75,"completionDate":"2031-03"},{"nctId":"NCT06207123","phase":"PHASE1,PHASE2","title":"A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-09-13","conditions":["Acute Leukemia","Lymphoblastic Leukemia","Lymphoblastic Lymphoma"],"enrollment":15,"completionDate":"2026-12-01"},{"nctId":"NCT06683833","phase":"PHASE4","title":"Comparison Between Egyptian MTA, Biodentine Versus Calcium Hydroxide as Indirect Pulp Capping Materials In Permanent Teeth","status":"RECRUITING","sponsor":"Cairo University","startDate":"2025-09-03","conditions":["Deep Caries","Indirect Pulp Capping","Mineral Trioxide Aggregate (MTA)","Calcium Hydroxide","Biodentine","Patient Reported Outcome Measures"],"enrollment":35,"completionDate":"2026-07-03"},{"nctId":"NCT06896669","phase":"NA","title":"Effects of Vitamin D and Calcium on Hyperglycemia and Dyslipidemia in Patients Gestational Diabetes","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2025-01-28","conditions":["Diabetes Mellitus, Gestational"],"enrollment":60,"completionDate":"2026-03-05"},{"nctId":"NCT07218900","phase":"PHASE2","title":"A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-13","conditions":["Dyslipidaemia"],"enrollment":76,"completionDate":"2026-09-30"},{"nctId":"NCT06918431","phase":"PHASE2","title":"Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-10-10","conditions":["B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","Lymphoblastic Lymphoma"],"enrollment":53,"completionDate":"2029-03-30"},{"nctId":"NCT06712719","phase":"NA","title":"Effects of Dietary Phosphorus on Phosphorus and Calcium Whole-Body Balance and Kinetics in Moderate CKD","status":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","startDate":"2026-05-01","conditions":["CKD"],"enrollment":14,"completionDate":"2027-05-28"},{"nctId":"NCT05552976","phase":"PHASE3","title":"A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-01-10","conditions":["Relapsed or Refractory Multiple Myeloma"],"enrollment":525,"completionDate":"2029-07-25"},{"nctId":"NCT04789733","phase":"NA","title":"The GUARDIAN Pilot Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2021-04-27","conditions":["General Surgery"],"enrollment":80,"completionDate":"2026-12-31"},{"nctId":"NCT05081999","phase":"PHASE4","title":"De-Adoption of Beta-Blockers in Patients With Stable Ischemic Heart Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alberta","startDate":"2023-01-30","conditions":["Stable Ischemic Heart Disease","Coronary Artery Disease","Beta-blocker Therapy"],"enrollment":59,"completionDate":"2026-12-31"},{"nctId":"NCT06469944","phase":"PHASE1,PHASE2","title":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-09-20","conditions":["Gastroesophageal Junction","Gastroesophageal Adenocarcinoma","Esophageal Neoplasms","Esophageal Cancer"],"enrollment":160,"completionDate":"2029-09-12"},{"nctId":"NCT07460960","phase":"PHASE2","title":"TRIal of STatin Therapy Effect on Androgen Status and Erectile functioN in Men","status":"RECRUITING","sponsor":"Lomonosov Moscow State University Medical Research and Educational Center","startDate":"2026-03-05","conditions":["Erectile Dysfunction Due to Arterial Disease","Atheroscleroses","Erectile Disfunction","Endothelial Dysfunction","Androgen Profile","Testosterone"],"enrollment":150,"completionDate":"2027-12"},{"nctId":"NCT07461649","phase":"NA","title":"Pharmacokinetic Study of Eicosapentaenoic Acid (EPA) and Calcium L-5-Methyltetrahydrofolate (L-5-MTHF) After Administration of CreNeuroS® CNS Fish Oil Plus Softgels in Healthy Subjects Under Fasting Conditions","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Credit Pharmaceutical Co., Ltd.","startDate":"2026-03-15","conditions":["Bioavailability and Pharmacokinetics"],"enrollment":32,"completionDate":"2026-05-10"},{"nctId":"NCT05958342","phase":"PHASE2","title":"CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial","status":"RECRUITING","sponsor":"Jason Sperry","startDate":"2024-06-30","conditions":["Trauma","Hemorrhage"],"enrollment":1050,"completionDate":"2028-03"},{"nctId":"NCT05690984","phase":"PHASE2","title":"Elimination of Minimal Residual Disease After Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-06-26","conditions":["Multiple Myeloma"],"enrollment":30,"completionDate":"2026-07"},{"nctId":"NCT05739383","phase":"PHASE3","title":"A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-03-09","conditions":["Primary Prevention of Atherosclerotic Cardiovascular Disease"],"enrollment":14078,"completionDate":"2029-04-16"},{"nctId":"NCT04883242","phase":"PHASE2","title":"Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-07-29","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":30,"completionDate":"2031-12-31"},{"nctId":"NCT06348108","phase":"PHASE1","title":"Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Alfred Chung, MD","startDate":"2025-07-28","conditions":["Multiple Myeloma","Refractory Multiple Myeloma","Relapsed Multiple Myeloma"],"enrollment":32,"completionDate":"2029-07-31"},{"nctId":"NCT07471516","phase":"PHASE1,PHASE2","title":"Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-02-25","conditions":["Congenital Dyserythropoietic Anemia (CDA)"],"enrollment":2,"completionDate":"2027-08-12"},{"nctId":"NCT05664477","phase":"PHASE2","title":"PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roberta Brinton","startDate":"2024-01-10","conditions":["Menopause","Cognitive Change","Brain Disorder, Metabolic"],"enrollment":100,"completionDate":"2027-01-31"},{"nctId":"NCT06734559","phase":"NA","title":"Assessment of Masseter Muscle With Ultrasonography","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harran University","startDate":"2025-01-30","conditions":["Acute Apical Periodontitis of Pulpal Origin"],"enrollment":60,"completionDate":"2026-03-11"},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":["Carcinoma, Pancreatic Ductal","Colorectal Neoplasms","Carcinoma, Non-Small-Cell Lung"],"enrollment":30,"completionDate":"2029-03-11"},{"nctId":"NCT02592317","phase":"PHASE1","title":"A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2016-02-12","conditions":["Prostatic Neoplasms, Castration-Resistant"],"enrollment":23,"completionDate":"2027-12-31"},{"nctId":"NCT07469241","phase":"PHASE2","title":"Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-10","conditions":["Advanced Esophageal Squamous Cell Carcinoma","Unresectable Esophageal Squamous Cell Carcinoma"],"enrollment":50,"completionDate":"2029-06-30"},{"nctId":"NCT07469956","phase":"PHASE2","title":"Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-31","conditions":["Pancreatic Cancer Resectable"],"enrollment":30,"completionDate":"2029-01-31"},{"nctId":"NCT01480869","phase":"PHASE3","title":"Study of Vitamin D Supplementation Tailored to Vitamin D Deficiency in Breast Cancer Patients","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2011-07","conditions":["Breast Cancer"],"enrollment":215,"completionDate":"2014-12"},{"nctId":"NCT03249389","phase":"NA","title":"Assessing the Changes in Markers of Calcium Vitamin Metabolism of for Breast Cancer Adjuvant (CALCIOBS)","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2015-10","conditions":["Breast Cancer"],"enrollment":146,"completionDate":"2016-09"},{"nctId":"NCT06879054","phase":"NA","title":"Lifestyle, Education, Activity, Nutrition (LEAN) Into Pregnancy","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-07-01","conditions":["Pregnancy","Preconception Education","Preconception Care, Preconception Risk","Adverse Pregnancy Outcomes"],"enrollment":200,"completionDate":"2029-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Gel, Injection, Liquid","formulations":[{"form":"GEL","route":"TOPICAL","productName":"Calgonate Calcium Gluconate Gel2.5%"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Calcium Gluconate"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"calcium gluconate"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"CALCIUM GLUCONATE"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Calcium Gluconate"},{"form":"LIQUID","route":"ORAL","productName":"Dairy Allergen Mix"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146426","MMSL":"20","NDDF":"000777","UNII":"SQE6VB453K","VUID":"4018087","CHEBI":"CHEBI:3309","VANDF":"4018087","RXNORM":"1298846","UMLSCUI":"C0006699","chemblId":"CHEMBL2106119","ChEMBL_ID":"CHEMBL2106119","KEGG_DRUG":"D00935","DRUGBANK_ID":"DB11126","PUBCHEM_CID":"9290","SNOMEDCT_US":"387292008","SECONDARY_CAS_RN":"66905-23-5","MESH_DESCRIPTOR_UI":"D002125"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Fresenius Kabi Usa","relationship":"Current Owner"}],"publicationCount":1640,"therapeuticAreas":["Bone"],"atcClassification":{"source":"DrugCentral","atcCode":"A12AA03","allCodes":["A12AA03","D11AX03"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 19","pmid":"41869998","title":"Hypocalcaemic Tetany and Seizures Secondary to Vitamin D Deficiency.","journal":"Irish medical journal"},{"date":"2026","pmid":"41800300","title":"Case Report: long-term calcaemia management in a dog after thyroidectomy and parathyroidectomy.","journal":"Frontiers in veterinary science"},{"date":"2026 Mar","pmid":"41798656","title":"Hydrofluoric Acid Cutaneous Burns: A Systematic Review of Emergency Management and General Surgical Sequelae.","journal":"Cureus"},{"date":"2026 Mar 7","pmid":"41795097","title":"Which calcium preparation should we use in paediatric resuscitation? A comprehensive review of basic physiology, pharmacokinetics, and clinical evidence.","journal":"Journal of anesthesia, analgesia and critical care"},{"date":"2025 Oct","pmid":"41783629","title":"Multiple Subcutaneous Calcifications in a Neonate after Intravenous Calcium Gluconate: A Case Report.","journal":"JNMA; journal of the Nepal Medical Association"}],"companionDiagnostics":[],"genericManufacturers":5,"_genericFilersChecked":true,"genericManufacturerList":["Amneal","B Braun Medical","Nivagen Pharms Inc","Sagent","Somerset"],"status":"approved","companyName":"Fresenius Kabi Usa","companyId":"","modality":"Small molecule","firstApprovalDate":"2017","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-10-29T00:00:00.000Z","mah":"HQ SPCLT PHARMA","brand_name_local":null,"application_number":"NDA210906"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-06-17T00:00:00.000Z","mah":"FRESENIUS KABI USA","brand_name_local":null,"application_number":"NDA208418"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-10-14T00:00:00.000Z","mah":"NIVAGEN PHARMS INC","brand_name_local":null,"application_number":"ANDA213071"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-09-05T00:00:00.000Z","mah":"AMNEAL","brand_name_local":null,"application_number":"ANDA217174"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-10-19T00:00:00.000Z","mah":"SOMERSET","brand_name_local":null,"application_number":"ANDA217689"},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":5,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T00:03:06.982765+00:00","fieldsConflicting":10,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}